Saros Therapeutics Secures $2M Award for Cancer Immunotherapy

North Chicago, Illinois, U.S., October 2, 2026

Saros Receives Second $2 Million Award

The new $2 million award follows an earlier award of the same amount, bringing total funding from the program to $4 million. The support is intended to accelerate Saros Therapeutics’ development activities and help advance its cancer-immunotherapy technology toward additional preclinical and translational milestones. As a Helix 51 company, Saros benefits from an ecosystem focused on supporting the commercialization of promising biomedical discoveries and technologies emerging from research institutions. The funding is particularly significant for an early-stage biotechnology company because advancing an experimental cancer therapy from laboratory research toward clinical development requires substantial resources for drug characterization, preclinical studies, manufacturing development, safety testing and regulatory preparation. Continued financial support can help bridge the gap between scientific discovery and therapeutic development while allowing researchers to generate the evidence needed for future clinical evaluation. Saros is developing its technology in collaboration with researchers and scientific partners associated with Rosalind Franklin University, creating a pathway for academic discoveries to move toward potential therapeutic applications. The latest award highlights continued interest in the company’s approach and provides additional resources for progressing its cancer-immunotherapy program.

Novel Immunotherapy Approach Targets Cancer

Cancer immunotherapy is an important area of modern drug development that seeks to harness or modify the patient’s immune system to recognize and eliminate malignant cells. Unlike conventional treatments that directly target rapidly dividing cells, immunotherapies can work by enhancing immune recognition, activating immune cells or modifying interactions within the tumor microenvironment. Saros Therapeutics is pursuing a technology designed to advance this concept by supporting the development of an immune-based approach to cancer treatment. The company’s research is focused on translating its underlying scientific platform into a therapeutic candidate that could potentially address limitations associated with existing cancer treatments. The program remains in development, and additional research will be required to establish its safety, efficacy and suitability for human clinical trials. The company’s progress reflects the broader pharmaceutical industry’s continued investment in next-generation cancer immunotherapies. Researchers worldwide are exploring new strategies to improve immune-cell activation, overcome tumor resistance and develop treatments that can provide more durable responses across different cancer types. Saros’ work contributes to this expanding field by investigating another potential route for using the immune system against cancer.

Funding Supports Translation Toward Clinical Development

The second $2 million award provides Saros with additional resources to advance its technology and conduct the research necessary to support future development decisions. For biotechnology companies working on innovative therapies, these development stages can include optimization of therapeutic candidates, evaluation of biological activity, assessment of potential toxicity and preparation for future regulatory interactions. The involvement of Rosalind Franklin University of Medicine and Science and the Helix 51 innovation ecosystem also illustrates the role that academic institutions and translational-development organizations can play in moving promising biomedical research toward commercialization. Such partnerships can provide biotechnology companies with access to scientific expertise, research infrastructure and development resources while helping promising technologies progress beyond the discovery stage.

Saros Therapeutics’ latest award therefore represents more than an additional source of funding. It provides continued support for the company’s efforts to advance a cancer immunotherapy platform and generate the scientific and development data required for future milestones. While the technology remains investigational and additional studies will be necessary before any potential clinical application can be established, the new funding marks continued momentum for Saros’ cancer-therapy development program. The award also underscores the growing importance of innovative immunotherapy approaches within the biopharmaceutical sector, where companies and academic researchers are working to develop therapies capable of engaging the immune system more effectively against cancer. Saros Therapeutics’ continued development efforts will determine how successfully its technology can progress toward clinical testing and, ultimately, whether it can become a viable therapeutic option for patients.

Source: Saros Therapeutics press release